themis Medicare Ltd. has reported consolidated financial results for the period ended June 30, 2024. nnThemis Medicare has posted net profit of Rs. 24.68 crores for the period ended June 30, 2024 as against net profit of Rs. 6.64 crores for the period ended March 31, 2024. The company posted net profit of Rs.18.19 crores for the period ended June 30, 2023.
Themis Medicare Ltd., a pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, has announced the launch of a novel transdermal Estradiol spray Lenzetto in the Indian market for treatment of menopausal symptoms.
Themis Medicare Limited revenue from operations stood at Rs. 91 crore in Q2 FY23, as against Rs. 107.39 crore in Q2 FY22, a decrease of 15.26%.
Themis Medicare, the Mumbai-based drug maker once known for paracetamol brand Metacin, is betting big on the repurposed drug inosine pranobex which was approved by Indian drug regulator for treating various viral respiratory infections including Covid.
Mumbai: Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID-19 and other acute viral respiratory infections.
In a landmark development for the treatment of COVID-19, Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the approval of its antiviral drug VIRALEX® by the Drug Controller General of India (DCGI). As per the results of a double-blind randomized controlled trials (RCT), the drug helps in early relief of the clinical symptoms in mild to moderate COVID-19 patients.
Themis Medicare Ltd. (Themis), a Mumbai-based pharmaceutical company, announced that the company’s antiviral drug Viralex received approval from the Drug Controller General of India (DCGI) for the treatment of Covid-19.
There aren't any vaccines or treatments for the painful viral infection chikungunya, but with phase 2 results announced this week, Themis hopes it's one step closer to changing that.
There aren't any vaccines or treatments for the painful viral infection chikungunya, but with phase 2 results announced this week, Themis hopes it's one step closer to changing that.
Even as the Drug Controller General of India (DCGI) has ordered withdrawal of the popular diclofenac painkiller injection marketed by Novartis India Ltd under the brand name Voveran three weeks back, physicians from across the country recommend diclofenac as gold standard in pain management amid safety concerns raised by health ministry.